Sonoma Pharmaceuticals (SNOA) EPS (Weighted Average and Diluted) (2013 - 2025)
Sonoma Pharmaceuticals (SNOA) recorded quarterly EPS (Weighted Average and Diluted) of -$0.48 in Q4 2025, down 50.0% quarter-over-quarter from -$0.32 in Q3 2025, and up 23.81% on a YoY basis from -$0.39 in Q4 2024.
Sonoma Pharmaceuticals (SNOA) EPS (Weighted Average and Diluted) (2013 - 2025) Analysis & Trends
Sonoma Pharmaceuticals' EPS (Weighted Average and Diluted) history runs 12 years deep, the most recent figure standing at -$0.48 for Q4 2025.
- In Q4 2025, EPS (Weighted Average and Diluted) rose 23.81% year-over-year to -$0.48; the TTM figure through Dec 2025 stood at -$1.95 (up 20.41% YoY), while the FY2025 annual figure was -$2.79, up 73.75% from the prior year.
- EPS (Weighted Average and Diluted) was -$0.48 for Q4 2025 at Sonoma Pharmaceuticals, down from -$0.32 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.11 in Q1 2024 to a low of -$5.75 in Q3 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.81 across 5 years, with a median of -$0.44 in 2025.
- The sharpest annual moves came in 2023 and 2024: EPS (Weighted Average and Diluted) slumped 1642.42% in 2023, then surged 128.54% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.31 in 2021, then slumped by 100.0% to -$0.62 in 2022, then sank by 156.45% to -$1.59 in 2023, then soared by 60.38% to -$0.63 in 2024, then grew by 23.81% to -$0.48 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.48 (Q4 2025), -$0.32 (Q3 2025), and -$0.76 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 0.31 |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 1.42 |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 5.82 |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 0.02 |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 1.91 |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 0.11 |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -0.40 |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 1.80 |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -0.40 |
| 10 | Sonoma Pharmaceuticals | 1.90 Mn | -659,569.98 | 1.65 Mn | -0.48 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.48 |
| Sep 30, 2025 | -0.32 |
| Jun 30, 2025 | -0.76 |
| Mar 31, 2025 | -0.39 |
| Dec 31, 2024 | -0.63 |
| Sep 30, 2024 | -0.59 |
| Jun 30, 2024 | -1.34 |
| Mar 31, 2024 | 0.11 |
| Dec 31, 2023 | -1.59 |
| Sep 30, 2023 | -5.75 |
| Jun 30, 2023 | -0.29 |
| Mar 31, 2023 | -0.39 |
| Dec 31, 2022 | -0.62 |
| Sep 30, 2022 | -0.33 |
| Jun 30, 2022 | -0.29 |
| Dec 31, 2021 | -0.31 |
| Sep 30, 2021 | -0.04 |
| Jun 30, 2021 | -0.52 |
| Dec 31, 2020 | -0.31 |
| Sep 30, 2020 | 0.06 |